Small cell lung carcinomaLung neoplasmsIncidenceSmokingThe incidence of small cell lung cancer (SCLC) is often quoted as 'around 20%' of all lung cancers but is reportedly decreasing over time. We analysed the trends in incidence of SCLC and compared these with the trends in lung cancer ...
Small cell lung cancer (SCLC) is one of a pathological type of lung cancer, and it is characterized by invasiveness, high malignancy and refractoriness. The mortality rate of SCLC is significantly higher than other types of lung cancer, and the treatment options for SCLC patients are limited. ...
Small cell lung cancer (SCLC) accounts for approximately 13% of all lung cancers, and it is a highly aggressive, poorly differentiated, high-grade neuroendocrine carcinoma2. Compared with non-small cell lung cancer (NSCLC), SCLC is characterized by a rapid multiplication time, early and ...
to experimentally test the relationship between Notch signaling, NE differentiation and intrinsic tumor immunity, we overexpressed the intracellular, transcriptionally active domain ofNOTCH1(N1ICD) in a NE human SCLC cell line (NCI-H82)
This study compared the survival outcomes after thermal ablation versus wedge resection in patients with stage I non-small cell lung cancer (NSCLC) ≤ 2 cm. Data from the United States (US) National Cancer Institute Surveillance Epidemiology a
Cancer Cell International (2022) 22:120 https://doi.org/10.1186/s12935-022-02505-1 Cancer Cell International PRIMARY RESEARCH Open Access The regulation of autophagy by the miR‑199a‑5p/p62 axis was a potential mechanism of small cell lung cancer cisplatin resistance Tiezhi...
Treatment policy of surgery in small cell carcinoma of the lung: retrospective analysis of a series of 874 consecutive patients. Thorax. 1985;40(4):272–7. https://doi.org/10.1136/thx.40.4.272. Article CAS PubMed PubMed Central Google Scholar Lad T, Piantadosi S, Thomas P, Payne D,...
Histology was classified as squamous cell carcinoma, adenocarcinoma, or other NSCLC, using International Classification of Diseases for Oncology Third Edition (ICD-O-3) codes adopted from Egevad et al20 and based on guidelines from the International Agency for Research on Cancer. In order to ...
The immunosuppressive tumor microenvironment (TME) remains a major obstacle to tumor control and causes suboptimal responses to immune checkpoint blockade (ICB) therapy. Thus, developing feasible therapeutic strategies that trigger inflammatory responses
Abbreviations: CPI, Checkpoint Inhibitor; HCPCS, Healthcare Common Procedure Coding System; NDC, National Drug Codes; ICD-9/10-CM, International Classification of Disease, Ninth or Tenth Revision, Clinical Modification; CPT, Current Procedureal Terminology; NSCLC, non-small cell lung cancer; PET, ...